Barriers to using warfarin in non-valvular atrial fibrillation [5]

British Medical Journal

Volumn 332, Issue 7536, 2006, Pages 303-304

  Gattellari, Melina ^a   Zwar, Nicholas A ^a   Worthington, John M ^b   Middleton, Sandy ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Liverpool Health Service   (Australia)

^c AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; GENERAL PRACTITIONER; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; AUSTRALIA; CEREBROVASCULAR ACCIDENT; FAMILY PRACTICE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; WARFARIN;

EID: 32544440467     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7536.303-b     Document Type: Letter

References (5)

1. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand S-L, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006;332:141-5. (21 January.)
2. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
3. Gage BF, Birman-Oevch E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005;118:612-7.
4. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing anti-thrombolic therapy for elderly patients with atrial fibrillation who are at risk of falls. Arch Intern Med 1999;109:677-85.
5. Evans A, Davis S, Kilpatrick C, Gerraty R, Campbell D, Greenberg P. The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. J Clin Neurosci 2002;9:268-72.